Results 61 to 70 of about 114,702 (262)

Targeting neoplastic B cells and harnessing microenvironment: the “double face” of ibrutinib and idelalisib [PDF]

, 2015
Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not suitable for high dose chemotherapy with autologous stem cell transplantation (ASCT) has a dismal prognosis and no standard therapy.
FIORCARI, STEFANIA, LUPPI, Mario, MAFFEI, Rossana, MARASCA, Roberto, MARTINELLI, Silvia, POTENZA, Leonardo   +5 more
core   +1 more source

Structure-based virtual screening and biological evaluation of novel small-molecule BTK inhibitors

Journal of Enzyme Inhibition and Medicinal Chemistry, 2022
Bruton tyrosine kinase (BTK) is linked to multiple signalling pathways that regulate cellular survival, activation, and proliferation. A covalent BTK inhibitor has shown favourable outcomes for treating B cell malignant leukaemia.
Tony Eight Lin, Li-Chin Sung, Min-Wu Chao, Min Li, Jia-Huei Zheng, Tzu-Ying Sung, Jui-Hua Hsieh, Chia-Ron Yang, Hsueh-Yun Lee, Er-Chieh Cho, Kai-Cheng Hsu   +10 more
doaj   +1 more source

HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib [PDF]

, 2016
Activating mutations in MYD88 are present in approximately 95% of patients with Waldenstrom Macroglobulinemia (WM), as well as other B-cell malignancies including ABC DLBCL. In WM, mutated MYD88 triggers activation of BTK. Ibrutinib, a pleiotropic kinase
Advani, Bohers, Cao, Cao, Cheng, Chng, Christopher J. Patterson, Evans, Farré, Gay, Guang Yang, Gutiérrez, Hallek, Hanke, Hong, Honigberg, Janz, Jennifer R. Brown, Jiaji G. Chen, Jie Chen, Jorge J. Castillo, Jourdan, Juilland, Lam, Leleu, Li Tan, Lian Xu, Messeguer, Musumeci, Nathanael Gray, Ngo, Nicholas Tsakmaklis, O’Boyle, Patricelli, Pecquet, Pene-Dumitrescu, Philip Cohen, Poh, Sahota, Saito, Sanner, Sara J. Buhrlage, Schaeffer, Shuai Liu, Steven P. Treon, Suh, Taguchi, Treon, Treon, Treon, Trott, Varettoni, Wei Zhang, Wilson, Woyach, Xia Liu, Xiaofeng Zhang, Xu, Yang, Yang, Zachary R. Hunter   +60 more
core   +2 more sources

The Possible Role of Bruton Tyrosine Kinase Inhibitors in the Treatment of COVID-19: A Review

Current Therapeutic Research, 2022
: Background: Coronavirus disease 2019 (COVID-19), an acute, sometimes severe respiratory illness caused by a novel coronavirus has led to a vast pandemic with an astonishing spread rate.
Mitra Rezaei, MD, Saghar Barati, Pharm-D, PhD, Abdolreza Babamahmoodi, MD, Farzaneh Dastan, Pharm-D, PhD, Majid Marjani, MD   +4 more
doaj   +1 more source

Emerging targets in human lymphoma: targeting the MYD88 mutation [PDF]

, 2016
B cell neoplasms co-opt the molecular machinery of normal B cells for their survival. Technological advances in cancer genomics has significantly contributed to uncovering the root cause of aggressive lymphomas, revealing a previously unknown link ...
Horikawa, Keisuke, Jeelall, Yogesh S., Wang, James Q.   +2 more
core   +1 more source

Phase I/II study of tirabrutinib, a second-generation Bruton’s tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma

Neuro-Oncology, 2020
Background The safety, tolerability, efficacy, and pharmacokinetics of tirabrutinib, a second-generation, highly selective oral Bruton’s tyrosine kinase inhibitor, were evaluated for relapsed/refractory primary central nervous system lymphoma (PCNSL ...
Y. Narita, M. Nagane, K. Mishima, Y. Terui, Y. Arakawa, Hajime Yonezawa, K. Asai, N. Fukuhara, K. Sugiyama, N. Shinojima, Junsaku Kitagawa, Arata Aoi, R. Nishikawa   +12 more
semanticscholar   +1 more source

Bruton Tyrosine Kinase Inhibitors

The Cancer Journal, 2019
Abstract Bruton tyrosine kinase (BTK) is a nonreceptor tyrosine kinase that plays a central role in the signal transduction of the B-cell antigen receptor and other cell surface receptors, both in normal and malignant B lymphocytes. B-cell antigen receptor signaling is activated in secondary lymphatic organs and drives the proliferation of ...
openaire   +3 more sources

How I Manage Chronic Lymphocytic Leukemia

Hematology Reports, 2023
Chronic lymphocytic leukemia (CLL), is a hematologic malignancy characterized by the uncontrolled proliferation of mature B lymphocytes. CLL is the most prevalent leukemia in Western countries.
Patrice Nasnas, Claudio Cerchione, Gerardo Musuraca, Giovanni Martinelli, Alessandra Ferrajoli   +4 more
doaj   +1 more source

Ibrutinib for B cell malignancies [PDF]

, 2014
Research over the role of Bruton’s agammaglobulinemia tyrosine kinase (BTK) in B-lymphocyte development, differentiation, signaling and survival has led to better understanding of the pathogenesis of B-cell malignancies.
Aileen Novero, Delong Liu, George Dous, Pavan M Ravella, Yamei Chen   +4 more
core   +1 more source

Targeting BTK for the treatment of FLT3-ITD mutated acute myeloid leukemia [PDF]

, 2015
Approximately 20% of patients with acute myeloid leukaemia (AML) have a mutation in FMS-like-tyrosine-kinase-3 (FLT3). FLT3 is a trans-membrane receptor with a tyrosine kinase domain which, when activated, initiates a cascade of phosphorylated proteins ...
A Puissant, AJ Mohamed, BD Smith, BJ Druker, C Chung, C Dos Santos, C Thiede, C Venkataraman, CC Smith, CK Hahn, F Heidel, F Honda, G Juliusson, H Kiyoi, HS Ma, J Adolfsson, JA Dubovsky, JA Dubovsky, JA Woyach, JA Woyach, JB Petro, K Fiedler, KU Birkenkamp, L Zaitseva, M Levis, M Nakao, ML Wang, N Feldhahn, NJ Horwood, PP Zarrinkar, Q Xu, RF Schlenk, RM Stone, S Knapper, S Meshinchi, SA Ezell, SA Rushworth, SA Rushworth, SA Rushworth, SA Rushworth, T Kindler, T Matsunaga, T Oellerich, T-l Gu, V Vijayan, W Gao, Y Alvarado, Y Baba, Y Yamamoto, Y-T Tai   +49 more
core   +2 more sources